Who are ticagrelor + aspirin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): clopidogrel + aspirin OR prasugrel + aspirin, Tirofiban+Oral Dual Antiplatelet Therapy, Standard-DAPT of Ticagrelor plus aspirin, Early Dual Antiplatelet Therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ticagrelor-aspirin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ticagrelor + aspirin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ticagrelor + aspirin (ticagrelor + aspirin) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet therapy. Area: Cardiovascular.

marketed Dual antiplatelet therapy P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ticagrelor + aspirin (ticagrelor + aspirin) — Sunnybrook Health Sciences Centre. Ticagrelor and aspirin work together to prevent blood clots by inhibiting platelet activation and aggregation through different pathways.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ticagrelor + aspirin TARGET	ticagrelor + aspirin	Sunnybrook Health Sciences Centre	marketed	Dual antiplatelet therapy	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
clopidogrel + aspirin OR prasugrel + aspirin	clopidogrel + aspirin OR prasugrel + aspirin	Abbott Medical Devices	marketed	Dual antiplatelet therapy (DAPT)	P2Y12 receptor (clopidogrel/prasugrel) and cyclooxygenase (aspirin)
Tirofiban+Oral Dual Antiplatelet Therapy	Tirofiban+Oral Dual Antiplatelet Therapy	Second Affiliated Hospital of Soochow University	marketed	Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy	Glycoprotein IIb/IIIa receptor
Standard-DAPT of Ticagrelor plus aspirin	Standard-DAPT of Ticagrelor plus aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor	P2Y12 receptor (ticagrelor); cyclooxygenase-1 (aspirin)
Early Dual Antiplatelet Therapy	Early Dual Antiplatelet Therapy	Beijing Tiantan Hospital	phase 3	Dual antiplatelet therapy (DAPT)	Cyclooxygenase (COX) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet therapy class)

Sunnybrook Health Sciences Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ticagrelor + aspirin — Competitive Intelligence Brief. https://druglandscape.com/ci/ticagrelor-aspirin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab